Silexion Therapeutics announces new data in SIL204

The company states: “Silexion Therapeutics (SLXN) announced that SIL204 has demonstrated activity against eleven human cell lines originating from 5 different organ cancer sites, each with a specific KRAS mutation. High inhibition was achieved with inhibition rates ranging between 83.5% to 99.7%, including the Company’s first data in gastric cancer and expanded validation in colorectal cancer. The new preclinical CTG (Cell Titer-Glo) assay results confirm SIL204’s activity in human tumor cell lines for clinically significant mutations such as G12R which is 17%1 of pancreatic cancer and has been difficult to inhibit by the small molecule KRAS inhibitors. This new data with the previously reported in silico finding that SIL204 is specific for KRAS but not the other RAS isozymes provide first human cell line data for validating SIL204’s therapeutic potential as a comprehensive pan-KRAS isoform selective inhibitor.” Ilan Hadar, Chairman and CEO of Silexion Therapeutics stated: “These results validate SIL204 as a true pan-KRAS therapeutic candidate, now demonstrating high activity against a range of different KRAS mutations across multiple cancer types. The ability to achieve near-complete inhibition across such a diverse range of mutations positions SIL204 uniquely in the competitive landscape. With coverage extending from the most common G12D and G12V mutations to rarer variants like G12R, G13D, and G13C, SIL204 supports Silexion in building a comprehensive solution for KRAS-driven cancers that could address a significantly broader patient population than existing targeted therapies.”